title: Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated?
abstract: Bisphosphonate therapy has revolutionized the care of patients with metastatic bone disease. With its demonstrated activity and anti-tumour effects in preclinical studies it was natural to transition these agents to testing in the adjuvant setting. Surprisingly, the results of adjuvant breast cancer trials have shown either modest or no benefit or even harm. We sought to explore whether there were specific patient cohorts or treatment strategies that were most likely to benefit from adjuvant bisphosphonate therapy. We compared trial designs, patient characteristics and outcomes from the six published and two presented randomized adjuvant bisphosphonate trials. Differences in trial design and patient populations make direct comparisons complicated. The most efficacious use of adjuvant bisphosphonates appears to be in patients with either biopsy evidence of osseous micrometastases, were post-menopausal or had estrogen receptor-positive tumours. Despite tremendous optimism regarding adjuvant bisphosphonate therapy, results from large trials are conflicting. Further investigation into factors influencing response to bisphosphonate treatment or selection of appropriate sub-groups of patients with desirable response characteristics is warranted.
authors.affiliation: Division of Medical Oncology, Ottawa Hospital and Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. mclemons@toh.on.ca
authors.forename: Mark
authors.initials: M
authors.lastname: Clemons
authors.forename: Kent
authors.initials: K
authors.lastname: Russell
authors.forename: Luis
authors.initials: L
authors.lastname: Costa
authors.forename: Christina L
authors.initials: CL
authors.lastname: Addison
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates